12 March 2024
Scancell Holdings plc
("Scancell" or the
"Company")
Scancell Announces its Attendance at
Upcoming Conferences
Scancell Holdings plc (AIM: SCLP),
the developer of novel immunotherapies for the treatment of cancer
and infectious disease, is pleased to confirm that it will be
presenting at, and will also attend, several upcoming conferences
and events. Presentations at these high-profile conferences follow
the significant recent progress that Scancell has made in both
pre-clinical and clinical development.
These include:
· 14th World
ADC taking place in London, UK from
12-15 March.
Mandeep Sehmi, Head of Business
Development, will be presenting at the conference.
Title: Glymab ADC for targeting cancers with high unmet
need
Date and Time: Wednesday
13th March 5pm GMT
· Oxford
Global - Biologics 2024 taking place in
London, UK from 13-15 March
Poonam Vagehla and Foram Dave,
Scientists at Scancell, will be presenting at the
conference.
Session Title: Nextgen
Multispecifics, Cell Engagers & Other New Modalities
Title: Glycan Targeting Antibodies
for T Cell Redirection
Date and Time: Friday
15th March at 3:10 pm GMT
· BIO-Europe
Spring in Barcelona, Spain from 18-20
March
Mandeep Sehmi, Head of Business
Development and Mireille Vankemmelbeke, PI at Scancell will be
attending the conference.
· 21st CIMT Annual
Meeting taking place in Mainz, Germany
from 15-17 May
Samantha Paston, Head of
Translational Research, will be attending the
conference.
If you would like to arrange a
meeting with management, please contact commercial.enquiries@scancell.co.uk.
-ENDS-
|
For further
information, please contact:
|
|
|
Scancell
Holdings plc
|
+44 (0) 20 3709 5700
|
|
Professor Lindy Durrant, CEO
Dr Jean-Michel Cosséry, Non-Executive
Chairman
|
|
|
Stifel Nicolaus
Europe Limited (Nominated Adviser and Joint Broker)
|
+44 (0) 20 7710 7600
|
|
Nicholas Moore/Samira Essebiyea (Healthcare Investment
Banking)
|
|
|
Nick Adams/Nick Harland (Corporate Broking)
|
|
|
WG Partners LLP
(Joint Broker)
|
+44 (0) 20 3705 9330
|
|
David Wilson/Claes Spang/Sathesh
Nadarajah/Erland Sternby
|
|
|
Panmure Gordon (UK)
Limited (Joint Broker)
|
+44 (0) 20 7886 2500
|
|
Freddy Crossley/Emma Earl (Corporate Finance)
|
|
|
Rupert Dearden (Corporate Broking)
|
|
About
Scancell
Scancell is a clinical stage
biopharmaceutical company that is leveraging its proprietary
research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant
unmet needs in cancer and infectious disease. The Company is
building a pipeline of innovative products by utilising its four
technology platforms: Moditope®
and ImmunoBody®
for vaccines and GlyMab® and
AvidiMab® for
antibodies.
Adaptive immune responses include
antibodies and T cells (CD4 and CD8), both of which can recognise
damaged or infected cells. In order to destroy such cancerous or
infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells
or drugs. The Company's unique approach is that its innovative
products target modifications of proteins and lipids. For the
vaccines (Moditope® and ImmunoBody®) this includes citrullination and homocitrullination of
proteins, whereas its mAb portfolio targets glycans or sugars that
are added onto proteins and / or lipids (GlyMab®) or
enhances the potency of antibodies and their ability to directly
kill tumour cells
(AvidiMab®).
For further information about Scancell, please
visit: https://www.scancell.co.uk/